Literature DB >> 9169295

Biphasic effects of 8-OH-DPAT on endurance of treadmill performance in the male rat.

S Ahlenius1, P Kaur, P Salmi.   

Abstract

Administration of the 5-HT1A receptor agonist 8-OH-DPAT produced a biphasic pattern of effects on endurance performance of rats walking on top of a treadmill drum ([symbol: see text] = 166 mm, 16 rpm; approximately 8 m min-1), with enhanced performance at a low dose (0.1 mg kg-1 s.c.) followed by impairment (0.2-0.8 mg kg-1). The partial 5-HT1A receptor agonist (-)-pindolol improved the performance in the low dose range (0.5-2.0 mg kg-1 s.c.), whereas a higher dose (8 mg kg-1) was ineffective. The 5-HT1A receptor antagonist WAY-100,635 produced an impaired performance at a low dose (12.5 micrograms kg-1 s.c.), with a recovery of performance at higher doses (50-200 micrograms kg-1). It is suggested that the inhibition of central serotonergic neurotransmission produced by stimulation or blockade of 5-HT1A auto- and post-synaptic receptors, respectively, results in an improved endurance performance on the treadmill, whereas stimulation of postsynaptic 5-HT1A receptors has the opposite action. In support of this contention, the impaired performance produced by a high dose of 8-OH-DPAT (0.8 mg kg-1) was antagonized by pretreatment with (-)-pindolol (2 mg kg-1 s.c.).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169295     DOI: 10.1016/s0924-977x(96)00386-0

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  2 in total

1.  Comment on: Chlorpheniramine exerts anxiolytic-like effects and activates prefrontal 5-HT systems in mice (Miyata S. et al., Psychopharmacology, 2009).

Authors:  Petros N Karamanakos
Journal:  Psychopharmacology (Berl)       Date:  2010-01-19       Impact factor: 4.530

2.  5-HT1A agonists: alcohol drinking in rats and squirrel monkeys.

Authors:  Sara D McKenzie-Quirk; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2003-03-26       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.